JP2010512407A - 新生物を処置するための組成物および方法 - Google Patents

新生物を処置するための組成物および方法 Download PDF

Info

Publication number
JP2010512407A
JP2010512407A JP2009541425A JP2009541425A JP2010512407A JP 2010512407 A JP2010512407 A JP 2010512407A JP 2009541425 A JP2009541425 A JP 2009541425A JP 2009541425 A JP2009541425 A JP 2009541425A JP 2010512407 A JP2010512407 A JP 2010512407A
Authority
JP
Japan
Prior art keywords
vegf
antibody
thalidomide
patient
relapsed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009541425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512407A5 (OSRAM
Inventor
ロバート ディー． マス
グレゴリー ディー． プラウマン
Original Assignee
ジェネンテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック インコーポレイテッド filed Critical ジェネンテック インコーポレイテッド
Publication of JP2010512407A publication Critical patent/JP2010512407A/ja
Publication of JP2010512407A5 publication Critical patent/JP2010512407A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009541425A 2006-12-11 2007-05-04 新生物を処置するための組成物および方法 Pending JP2010512407A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (2)

Publication Number Publication Date
JP2010512407A true JP2010512407A (ja) 2010-04-22
JP2010512407A5 JP2010512407A5 (OSRAM) 2012-06-14

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541425A Pending JP2010512407A (ja) 2006-12-11 2007-05-04 新生物を処置するための組成物および方法

Country Status (17)

Country Link
US (1) US20100086544A1 (OSRAM)
EP (1) EP2099489B1 (OSRAM)
JP (1) JP2010512407A (OSRAM)
KR (1) KR101320198B1 (OSRAM)
CN (1) CN101547705B (OSRAM)
AU (1) AU2007333565A1 (OSRAM)
BR (1) BRPI0717688A2 (OSRAM)
CA (1) CA2670707A1 (OSRAM)
DK (1) DK2099489T3 (OSRAM)
IL (1) IL198852A (OSRAM)
MX (1) MX2009006202A (OSRAM)
NZ (1) NZ577058A (OSRAM)
RU (1) RU2482877C2 (OSRAM)
SG (1) SG177891A1 (OSRAM)
SI (1) SI2099489T1 (OSRAM)
WO (1) WO2008073509A2 (OSRAM)
ZA (1) ZA200903489B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
PL2488204T3 (pl) 2009-10-16 2016-10-31 Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
DK3485903T5 (da) 2011-09-23 2024-09-02 Mereo Biopharma 5 Inc Vegf/dll4-bindende midler og anvendelser deraf
AU2013232208B2 (en) * 2012-03-14 2017-04-27 Indiana University Research And Technology Corporation Compounds and methods for treating leukemia
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
DK3330259T3 (da) 2015-07-27 2020-08-10 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
DK3328843T3 (da) 2015-07-27 2023-01-09 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
AU2016299486B2 (en) 2015-07-27 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3331864B1 (en) 2015-08-04 2021-11-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
MX384527B (es) 2015-10-12 2025-03-14 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
ES3009668T3 (en) 2018-01-26 2025-03-31 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
TWI748491B (zh) 2019-05-31 2021-12-01 韓商鐘根堂股份有限公司 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑高鄰苯二甲醯亞胺衍生化合物及包含彼之醫藥組合物
EP4065150A4 (en) 2019-11-25 2023-12-06 The Regents of the University of California LONG-ACTING VEGF INHIBITORS FOR INTRAVASCULAR NEOVASCULARIZATION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012359A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
AU763361B2 (en) * 1998-09-25 2003-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/CDK complexes
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012359A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BRUCKNER,H.W. ET AL, ANTICANCER RESEARCH, vol. 25, no. 5, JPN6012029579, 2005, pages 3637 - 9, ISSN: 0002246337 *
BURSTEIN,H.J. ET AL: "Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory", BREAST CANCER RESEARCH AND TREATMENT, vol. 76, JPN6013030893, 2002, pages 115, ISSN: 0002565512 *
CAMPBELL,R.A. ET AL, INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 28, no. 6, JPN6012029585, June 2006 (2006-06-01), pages 1409 - 1417, ISSN: 0002246339 *
CHAUHAN,D. ET AL, BLOOD, vol. 104, no. 8, JPN6012029582, 2004, pages 2458 - 2466, ISSN: 0002246338 *
CHEN,H.X. ET AL, JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 21, JPN6013030888, July 2006 (2006-07-01), pages 3354 - 3360, ISSN: 0002565515 *
D'ADAMO,D.R. ET AL, JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 28, JPN6013030885, 2005, pages 7135 - 7142, ISSN: 0002565513 *
DENZ,U. ET AL, EUROPEAN JOURNAL OF CANCER, vol. 42, no. 11, JPN6012029577, July 2006 (2006-07-01), pages 1591 - 600, ISSN: 0002246336 *
FRIEDMAN,H.S.: "Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment", ONCOLOGY REPORT, vol. Vol.Fall, JPN6013030895, September 2006 (2006-09-01), pages 11, ISSN: 0002565516 *
HERBST,R. ET AL: "A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizuma", EJC SUPPLEMENTS, vol. 4, no. 12, JPN6013030897, November 2006 (2006-11-01), pages 20, XP025026429, ISSN: 0002565518, DOI: 10.1016/S1359-6349(06)70059-3 *
RYAN,C.J. ET AL, UROLOGIC ONCOLOGY, vol. 24, no. 3, JPN6013030889, June 2006 (2006-06-01), pages 250 - 253, ISSN: 0002565514 *
SIEGEL,D.S. ET AL, BLOOD, vol. 108, no. 11, JPN6012029588, November 2006 (2006-11-01), pages 1022, ISSN: 0002246335 *
SOMLO,G. ET AL: "Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory", BLOOD, vol. 106, no. 11, JPN6013030884, 2005, pages 723A, ISSN: 0002565511 *
WRIGHT,J.D. ET AL, GYNECOLOGIC ONCOLOGY, vol. 103, no. 2, JPN6013030891, November 2006 (2006-11-01), pages 489 - 493, ISSN: 0002565517 *

Also Published As

Publication number Publication date
BRPI0717688A2 (pt) 2013-01-22
CA2670707A1 (en) 2008-06-19
RU2009126588A (ru) 2011-01-20
NZ577058A (en) 2012-04-27
DK2099489T3 (da) 2014-08-18
WO2008073509A3 (en) 2009-01-08
RU2482877C2 (ru) 2013-05-27
KR20090087908A (ko) 2009-08-18
EP2099489A2 (en) 2009-09-16
SG177891A1 (en) 2012-02-28
AU2007333565A1 (en) 2008-06-19
SI2099489T1 (sl) 2014-09-30
CN101547705A (zh) 2009-09-30
CN101547705B (zh) 2013-06-12
HK1131064A1 (en) 2010-01-15
KR101320198B1 (ko) 2013-10-30
IL198852A (en) 2013-06-27
IL198852A0 (en) 2011-08-01
EP2099489B1 (en) 2014-05-21
WO2008073509A2 (en) 2008-06-19
ZA200903489B (en) 2010-08-25
MX2009006202A (es) 2009-06-22
US20100086544A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
CN101547705B (zh) 用于治疗新生物的组合物和方法
DK2646470T3 (en) ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
JP2020114840A (ja) がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤
CN112203695B (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
JP7545983B2 (ja) 抗ｖｅｇｆ抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いてがんを治療する方法
CN119868579A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
JP2011504092A (ja) 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体
CA2849746A1 (en) Anti-icam-1 antibodies to treat multiple-myeloma related disorders
WO2018067819A1 (en) Compositions and methods for treatment of cancers
CN110997724A (zh) 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
JP2023025036A (ja) がんの処置のためのアベルマブの投与レジメン
CN116744970A (zh) 包含sfrp2拮抗剂的组合物和方法
EP4489789A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
CN112638392A (zh) 组合疗法
JP2021533090A (ja) 併用療法
JP7520726B2 (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト
US20240366777A1 (en) Anti-folate receptor conjugate combination therapy with bevacizumab
JP2024533439A (ja) 併用療法
AU2018203727A1 (en) Compositions and methods for treating a neoplasm
HK1131064B (en) Compositions and methods for treating a neoplasm
AU2014201911A1 (en) Compositions and methods for treating a neoplasm
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
WO2024213081A1 (zh) 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
HK40029255A (en) Anti-cd47 agent-based ovarian cancer therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120910

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140317